Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2000-07-14
2003-04-01
Park, Hankyel T. (Department: 1648)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C424S184100, C424S185100, C424S186100, C424S188100, C424S199100, C424S202100, C424S204100, C424S208100, C530S300000, C530S350000, C536S023100, C435S320100
Reexamination Certificate
active
06541458
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to genes of particular strains of feline caliciviruses, to the proteins encoded by these genes, and their use for the production of immunogenic preparations and of recombinant or subunit vaccines against feline calicivirosis. These immunogenic preparations and these vaccines may also be combined with immunogenic preparations or vaccines prepared on the basis of other feline pathogens, for the production of multivalent immunogenic preparations and vaccines.
BACKGROUND OF THE INVENTION
Feline caliciviruses (FCV) were first described in 1957 (Fastier L. B. Am. J. Vet. Res. 1957. 18, 382-389). Feline caliciviruses are, with the feline herpesviruses, the two principal sources of viral diseases of the upper respiratory tract in cats. The FCV viruses affect a large number of animals, with FCV carrying rates of the order of 15 to 25%, and an anti-FCV seroprevalence of 70 to 100% (Coutts et al. Vet. Rec. 1994. 135. 555-556; Ellis T. M. Australian Vet. J. 1981. 57. 115-118; Harbour et al. Vet. Rec. 1991. 128. 77-80; Reubel et al. Feline Dendistry 1992. 22. 1347-1360). After an initial phase of hyperthermia, these respiratory diseases are generally accompanied by buccal ulcerations (palate, tongue, lips, nose), rhinitis, conjunctivitis, possibly anorexia and asthenia. The FCV viruses can also cause pneumonia, enteritis, and articular pain (lameness syndrome).
The FCV virus is transmitted only horizontally, there is no vertical transmission from the mother to its kitten during gestation (Johnson R. P. Res. Vet. Sci. 1984. 31. 114-119). FCV is transmitted by contact between infected animals and healthy animals or by the airways during sneezing (Wardley R C. Arch. Virol. 1976. 52. 243-249).
Feline caliciviruses are naked viruses of the Caliciviridae family; they possess a single-stranded positive RNA of about 7.7 kilobase pairs (kbp) in size (Carter M. J. Arch. Virol. 1994. 9. 429-439).
Like many RNA viruses, a large heterogeneity exists within the viral population of FCV. The antigenic variations, demonstrated since the beginning of the 70s by cross-serum neutralization experiments, make it possible to classify the FCVs into several viral strains or quasispecies (Radfoord et al. Proc. 1
st
Int. Symp. Caliciviruses ESVV 1997. 93-99).
Several FCV strains have been isolated and sequenced, in particular the strain F9 (Carter et al. Arch. Virol. 1992. 122. 223-235, sequence deposited in the GenBank databank under the accession number M86379), FCI (Neill et al. J. Virol. 1991. 65. 5440-5447, GenBank accession number U13992 and M32819), Urbana or URB (Sosnovtsev and Green Virology 1995. 210. 383-390, GenBank accession number L40021), F4 (Tohya et al. Arch. Virol. 1991. 117. 173-181, GenBank accession numbers D31836 and D90357), KCD (Fastier L. B. Am. J. Vet. Res. 1957. 18. 882-889, GenBank accession number L09719), LLK (GenBank accession number U07131), NADC (GenBank accession number L09718), 2280 (GenBank accession number X99445) and 255 (Kahn and Gillepsie. Cornell Vet. 1970. 60. 669-683, GenBank accession number U07130).
Vaccination against FCV was introduced since the end of the 70s from attenuated FCV strains, mainly strain F9 isolated in 1958 by Bittle (Bittle et al. Am. J. Vet. Res. 1960. 21. 547-550) or strains derived from F9 by passage in vitro or in vivo (“F9-like”).
Inactivated vaccines are also available. They use strains 255 and 2280, which were isolated respectively in 1970 in a cat with a pneumonia (Kahn and Gillepsie. Cornell Vet. 1970. 60. 669-683) and in 1983 in a cat suffering from lameness (Pedersen et al. Fel. Prac. 1983. 13. 26-35).
The humoral response is essentially directed against the capsid protein, also called p65 (Guiver et al. J. Gen. Virol. 1992. 73. 2429-2433). The genes encoding the capsid protein of many feline caliciviruses have been sequenced and compared without it being possible to distinguish more clearly certain sequences (Glenn et al. Proc. 1
st
Int. Symp. Caliciviruses ESW 1997. 106-110; Geissler et al. Virus Res. 1997. 48. 193-206; Neill et al. Proc. 1
st
Int. Symp. Caliciviruses ESVV 1997. 120-124).
The gene encoding the capsid protein has also been cloned and expressed in various expression systems, in particular the gene encoding the capsid protein of the KS20 FCV virus in plasmids (Geissler et al. J. Virol. 1999. 73. 834-838), the genes encoding the capsid proteins of the CFI-68, JOK63, JOK92, LS012 and F9 FCV viruses in baculoviruses (DeSilver et al. Proc. 1
st
Int. Symp. Caliciviruses ESVV 1997. 131-143), the gene encoding the capsid protein of the F4 FCV virus in type 1 feline herpesviruses (Yokoyama et al. J. Vet. Med. Sci. 1998. 60. 717-723). These various constructs have allowed the production of recombinant capsid proteins.
Because of antigenic drift over time, antisera produced against old vaccine strains isolated in the 60-70s, such as strains F9, 255 or 2280, neutralize only few isolates of the 90s. For example, the anti-F9 serum neutralizes 43% of the isolates of the period 1990-1996, against 56% for the period 1980-89 and 86% for the period 1958-79, and only 10% of the English isolates of the period 1990-96 (Lauritzen et al. Vet. Microbiol. 1997. 56. 55-63).
BRIEF SUMMARY OF THE INVENTION
The objective of the present invention is the detection of FCV strains, which induce in cats antibodies against a broad cross-neutralization spectrum.
The objective of the invention is in particular, starting with selected strains, the isolation and characterization of genes encoding immunogenic proteins which can be used for vaccination against feline calicivirosis.
Another objective of the invention is to provide recombinant in vitro and in vivo expression vectors containing and expressing at least one such nucleotide sequence.
Yet another objective of the invention is to provide immunogenic preparations or vaccines against feline calicivirosis.
Yet another objective of the invention is to provide multivalent immunogenic preparations and multivalent vaccines against feline calicivirosis and against at least one other feline pathogen.
REFERENCES:
patent: 5679356 (1997-10-01), Bonnem et al.
patent: 5716822 (1998-02-01), Wardley et al.
patent: 5858373 (1999-01-01), Paoletti et al.
patent: 5910488 (1999-06-01), Nabel et al.
patent: 5951988 (1999-09-01), Little-van den Hurk et al.
patent: 5989561 (1999-11-01), Paoletti et al.
patent: 786 518 (1991-07-01), None
patent: 0 737 750 (1996-10-01), None
patent: WO 98/56929 (1988-12-01), None
patent: WO 91/01332 (1991-02-01), None
patent: WO 94/16716 (1994-08-01), None
patent: WO 96 39177 (1996-12-01), None
patent: WO 98/03660 (1998-01-01), None
patent: WO 98/21354 (1998-05-01), None
Lauritzen, A. et al., “Serological analysis of feline calcivirus isolates from the United States and United Kingdom.” Veterinary Microbiology 1997 56:55-63.
Yokoyama, N. et al., “Further development of a recombinant feline herpesvirus type 1 vector expressing feline calicivirus immunogenic antigen.” J. Vet. Med. Sci. 1998 60(6):717-723.
DeSilver, D.A. et al., “Expression of the complete capsid and the hypervariable region of feline calicivirus in the baculovirus expression system.” Proc. 1stInt. Symp. Caliciviruses ESVV 1997 pp. 131-143.
Glenn, M.A. et al., “Feline claicivirus strain F65-capsid gene sequence and implications for pathogenicity.” Proc. 1stInt. Symp. Caliciviruses ESVV 1997 pp. 106-110.
Geissler, K. et al., “Genetic and antigenic heterogeneity among feline calicivirus isolates form distinct disease manifestations.” Virus Research 1997 48:193-206.
Geissler, K. et al., “Feline calicivirus capsid protein expression and capsid assembly in cultured feline cells.” Journal of Virology Jan. 1999 73(1):834-838.
Guiver, M. et al., “The cloning sequencing and expression of a major antigenic region from the feline calicvirus capsid protein.” Journal of General Virology Sep. 1992; 73 ( Pt 9):2429-33.
Green, K.Y., et al., “expression and self-assembly of recombinant capsid protein from the antigenically distinct Hawaii human calcivirus.” Journal of Clinical Microbiology Jul.
Audonnet Jean-Christophe Francis
Baudu Philippe Guy Nicolas
Brunet Sylvie Claudine
Brown Stacy S.
Frommer William S.
Frommer & Lawrence & Haug LLP
Kowalski Thomas J.
Merial
LandOfFree
Feline calicivirus genes and vaccines in particular... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Feline calicivirus genes and vaccines in particular..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Feline calicivirus genes and vaccines in particular... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3043761